Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency

Richard L. Wasserman(ENT and Allergy), Johann Bichler(CSL (Switzerland)), John W. Sleasman(University of South Florida), Joseph A. Church(University of Southern California), Hans Peter(University Medical Center Freiburg), Isaac Melamed, Mark R. Stein(Allergy Associates of the Palm Beaches)
European Journal of Pharmaceutical Sciences
March 7, 2009
10.1016/j.ejps.2009.02.014
Cited by 48

Related Papers

The EUROclass trial: defining subgroups in common variable immunodeficiency
|Blood|2007|860
Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency
|Nature Immunology|2003|730
Severe deficiency of switched memory B cells (CD27+IgM−IgD−) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease
|Blood|2002|626
ICOS Deficiency Is Associated with a Severe Reduction of CXCR5+CD4 Germinal Center Th Cells
|The Journal of Immunology|2006|376
A New Type of Perinuclear Anti-Neutrophil Cytoplasmic Antibody (p-ANCA) in Active Ulcerative Colitis but not in Crohn's Disease
|Immunobiology|1990|226